A University of Arkansas for Medical Sciences (UAMS)-based program will use $614,117 from three recent grants to expand biomedical research in Arkansas.
The three grants are administrative supplements to the Arkansas IDeA Network for Biomedical Research Excellence (INBRE) Program, awarded by the National Institute of General Medical Sciences at the National Institutes of Health (NIH).
CET
Validan unas nuevas pruebas de ADN del cáncer en sangre
Archivo - Extracción de sangre para pruebas del coronavirus en un centro de salud vasco - H. BILBAO / EUROPA PRESS - Archivo
MADRID, 14 Jun. (EUROPA PRESS) -
Un equipo internacional ha presentado los resultados de una evaluación independiente de cinco ensayos disponibles en el mercado para la secuenciación del ADN tumoral, un método rápido, barato y menos invasivo para diagnosticar y controlar el cáncer.
Los investigadores revelaron que todos los ensayos podían detectar de forma fiable el llamado ADN tumoral circulante (ADNc) cuando constituía el 0,5% del ADN total en sangre, un nivel de sensibilidad que permite la detección, el análisis genético y el seguimiento de los tumores en fase avanzada y metastásicos.
Several liquid biopsy products have the ability to detect tumor DNA circulating in a patient’s blood, according to an analysis that simulated the sensitivity of these products, provided the genetic variations linked to these cancers are sufficiently numerous in the sample to be captured by the test. The biopsies are much less reliable at detecting signs of cancer as variant frequency declines, which is often the case when a cancer is at an early stage. The study was published April 12 in
Although the relationship between the proportion of tumorous to healthy DNA in circulation and liquid biopsy performance was already known, this study is unique in that the authors used standardized samples of circulating tumor DNA (ctDNA) to compare the effectiveness of five research products, produced by Roche, Illumina, Integrated DNA Technologies, Burning Rock Dx, and Thermo Fisher Scientific. While company officials were part of the study, its authors say that industry representatives did no
Researchers have independently validated industry-leading blood tests that can detect the DNA released by tumours.
An international team today reports the findings of an independent assessment of five commercially-available assays for tumour DNA sequencing – a fast, cheap and less invasive method to diagnose and monitor cancer.
The researchers revealed that all assays could reliably detect so-called circulating tumour DNA (ctDNA) when it made up 0.5% of the total DNA in blood, a level of sensitivity that allows detection, genetic analysis and monitoring of late-stage and metastatic tumours.
Published in the journal Nature Biotechnology, the study is a major milestone for the use of ctDNA assays as cancer diagnostics, outlining best-practice guidelines and uncovering key areas of future development.